IQVIA’s (IQV) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of IQVIA (NYSE:IQV) in a report released on Monday morning,Benzinga reports. The firm currently has a $270.00 target price on the medical research company’s stock.

A number of other equities research analysts have also commented on IQV. Redburn Atlantic started coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Morgan Stanley reduced their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Stock Down 1.6 %

NYSE:IQV opened at $197.64 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a market cap of $35.87 billion, a PE ratio of 26.35, a P/E/G ratio of 2.25 and a beta of 1.48. The company’s 50 day moving average is $200.77 and its two-hundred day moving average is $218.81.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts anticipate that IQVIA will post 10.81 EPS for the current year.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Large investors have recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of IQVIA during the fourth quarter worth $336,041,000. Raymond James Financial Inc. acquired a new position in IQVIA during the fourth quarter worth about $236,120,000. American Century Companies Inc. grew its stake in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after acquiring an additional 905,960 shares in the last quarter. FMR LLC raised its holdings in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA in the 3rd quarter worth approximately $147,683,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.